Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 expressing solid tumors. It also develops CHM CORE-NK that is in phase Ia/IIb clinical trials for acute myeloid leukaemia/colorectal cancer and acute myeloid cancer, as well as in preclinical trials for blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.

Chimeric Therapeutics Ltd

Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD

Founder & Executive Chairman

Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.

CFO, Joint Company Secretary & Director

Dr. Rebecca  McQualter

Chief Operating Officer

Mr. Jason B. Litten M.D.

Chief Medical Officer

Mr. Kelly R. Thornburg

VP & Head of Quality

Mr. Nathan  Jong C.A.

Joint Company Secretary

Chimeric Therapeutics Ltd (CHM) Stock Analysis, Discussion Forum and Financial Metrics - ASX Exchange

Chimeric Therapeutics Ltd (CHM) Earnings Report Date and History | ASX

CHM's next earnings is on May 13, 2025 (Before Market Open)

When is the earnings report for CHM?

CHM Earnings History

CHM Stock Discussion Forum and Message Board

News for ASX: CHM